Gilead cash pile burns hole in investors' pockets
San Francisco
IN THE drug industry's biggest-ever period for deals, one wildly successful company with a multibillion-dollar war chest has been oddly silent. So what's Gilead Sciences Inc waiting for?
Drugmakers have done US$179 billion worth of mergers and acquisitions so far this year, on pace to top last year's US$221 billion record. Gilead has stayed on the sidelines, holding US$10.6 billion in cash and equivalents. The company reports second quarter earnings on Tuesday, and M&A will be on shareholders' minds.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Sheng Siong Q1 net profit up 9.3% on higher revenue
Nestle sales growth sputters on US slump, vitamin snags
Hermes Q1 sales jump 17% on strong China demand
Cordlife’s independent auditor to retire after issuing disclaimer of opinion on FY2023 financials
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO
Cordlife customers push for legal action